Shares of Thousand Oaks-based Atara Biotherapeutics finally saw a huge lift on the week of July 21, as the company announced that the U.S. Food and Drug Administration has accepted the filing of its Biologics License Application for tabelecleucel, the main product in its pipeline. Announced July 24, shares had been gaining traction fast as…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
